Engineering Cancer Cells by Adenovirus

Equipped with advanced technology platforms and extensive expertise, Creative Biolabs is dedicated to developing complete engineering cancer cells by adenovirus-related services for our global clients.

Introduction of Adenovirus Vector

Gene therapy is considered the “medicine of the 21st century”. With the development of synthetic vectors, virus vector-based gene delivery systems are considered to be the most effective for clinical application. Currently used virus vectors include herpes simplex virus, adenovirus, adeno-associated virus, retrovirus, and lentivirus. Among them, the ability of adenoviruses could efficiently infect and deliver genes to a range of cells and to be produced high titers, which has led to their wide application.

Among them, adenovirus vector (Ad) is the most commonly used viral vector in gene therapy clinical trials to the following advantages:

• Adenovirus vector has a large packaging capacity (~8.0 kb).
• At the equivalent scale, Ad can achieve up to 1000-fold higher titer vector stock compared with other viral vectors, such as retrovirus, lentivirus, and adeno-associated virus.
• Adenovirus vector can deliver transgene not only to the nucleus of dividing cells, but also to the nucleus of non-dividing cells with the highest efficiency among the gene delivery vectors.
• Adenovirus vector doesn’t present high genetic toxicity as it doesn’t integrate the transgene into the host genome.

Adenovirus Vector Applied in Anticancer Therapies

Adenovirus vectors have been used in gene therapy clinical trials in adult patients with a variety of diseases, covering several cancer types as well as cardiac diseases. Adenovirus vectors are applied to cancer treatment in three main therapeutic categories. In the first approach, replication-deficient (RD) AdVs are used to deliver immune-related genes/epitopes directly to tumor cells due to their immunogenic properties in order to attract and induce local anti-tumor immune responses. In the second type of strategy, the replication-competent (RC) AdVs can be applied to replicate preferentially within cancer cells, and achieve oncolysis performance by performing the natural lytic life cycle of the virus in cancer cells. Finally, either replication-deficient (RD) or replication-competent (RC) AdVs can be used to deliver and/or overexpress tumor-suppressor genes or cytotoxic/suicide genes within cancer cells, directly inducing an intrinsic cytotoxic cascade, causing cell cycle arrest, or triggering apoptosis.

Fig.1 The anticancer effect of oncolytic adenoviruses (CRAdVs). (Lee, et al., 2017)

Engineering Cancer Cells by Adenovirus

To better provide synthetic gene circuit strategies for cancer immunotherapy, Creative Biolabs is dedicated to providing engineering cancer cells by adenovirus-related services to help our clients meet their program requirements. We are dedicated to providing high-quality assay service development to facilitate our clients’ scientific research. And our scientists and technicians are experienced in every step with high dedication to ensuring accurate outcomes.

Moreover, our services include but are not limited to:

• Self-destruction Assays
• Ex Vivo Immune Reactivity Assessment of Self-destruction Cancer Cells
• Toxicity Assessment of Self-destruction Cancer Cells by Serum Chemistry

For more details about our related service, please contact us to discuss your project.

Reference

1. Lee, C.S.; et al. Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes & diseases. 2017, 4(2): 43-63.

For Research Use Only | Not For Clinical Use